891783-57-6

Basic information

• Product Name: 2H-Pyran-3(4H)-one, 6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]dihydro-
• CAS NO: 891783-57-6
• Molecular Formula: C22H28O3Si
• Molecular Weight: 368.548
• Mol File: 891783-57-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2H-Pyran-3(4H)-one, 6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-3(4H)-one, 6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]dihydro-(891783-57-6)
• EPA Substance Registry System: 2H-Pyran-3(4H)-one, 6-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]dihydro-(891783-57-6)

Safety Data

• Hazardous Substances Data: 891783-57-6(Hazardous Substances Data)

Upstream product

• 3749-36-8 2-hydroxymethyl-3,4-dihydro-2H-pyran 
• 100-73-2 acrolein dimer 
• 873309-58-1 tert-butyl ((3,4-dihydro-2H-pyran-2-yl)methoxy)diphenylsilane 

Downstream Products

• 1408074-42-9 racemic 5-((tert-butoxycarbonyl)amino)tetrahydro-2H-pyran-2-carboxylic acid 

Relevant articles and documents

Amide derivative and preparation method thereof and medical application

The invention relates to an amide derivative and a preparation method thereof and medical application, in particular to a compound in the formula (I) and pharmaceutically acceptable salt thereof or astereisomer, a preparation method of the compound and ap

Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine

In our effort to further understand interaction of novel pyran derivatives with monoamine transporters, we have designed, synthesized, and biologically characterized side-chain-extended derivatives of our earlier developed cis- and trans-(6-benzhydryl-tetrahydro-pyran-3-yl)-benzylamine derivatives. Both 3- and 6-position extensions were explored. All synthesized derivatives were tested for their affinities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuring their potency in inhibiting the uptake of [3H]DA, [3H]5-HT, and [3H]NE, respectively. Compounds were also tested for their binding affinity at the DAT by their ability to inhibit binding of [3H]WIN 35, 428. The results indicated that extension at the 3-position resulted in loss of activity compared to the original compound I. On the other hand, extension at the 6-position resulted in improvement of activity in the compound cis-12 by 2-fold over the parent compound I indicating favorable interaction. In addition, two glycoside derivatives were designed, synthesized, and biologically characterized. The glycosidic trans-isomer 24 exhibited highest potency for the NET in the current series of compounds.